Загрузка...
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
BACKGROUND: Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone...
Сохранить в:
| Опубликовано в: : | Cancer Med |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7433809/ https://ncbi.nlm.nih.gov/pubmed/32608149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3209 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|